A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

被引：4
|
作者：
Minh Diem Vu [1 ]
Moser, Samuel [2 ]
Delon, Camille [2 ]
Latzko, Melanie [2 ]
Gianotti, Reto [2 ]
Lueoend, Remo [2 ]
Friang, Chloe [2 ]
Murr, Ramona [2 ]
Duerner, Lydia Jasmin [2 ]
Weinzierl, Tina [2 ]
Fauti, Tanja [2 ]
Bacac, Marina [2 ]
Ast, Oliver [2 ]
Freimoser-Grundschober, Anne [2 ]
Diaz, Tea Rodriguez [2 ]
Zielonka, Joerg [2 ]
van Puijenbroek, Erwin [2 ]
Hosse, Ralf [2 ]
Bruenker, Peter [2 ]
Moessner, Ekkehard [2 ]
Klein, Christian [2 ]
Umana, Pablo [2 ]
Strein, Klaus [1 ]
机构：
[1] EngMab AG, Wilen, Switzerland
[2] Roche Innovat Ctr Zurich, Schlieren, Switzerland
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.2998.2998
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Garfall, Alfred L.
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita Y.
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Donk, Van De N. W.
    Moreau, P.
    Garfall, A. L.
    Bhutani, M.
    Oriol, A.
    Nooka, A. K.
    Martin, T. G.
    Rosinol, L.
    Mateos, M. -V.
    Bahlis, N.
    Popat, R.
    Besemer, B.
    Lopez, Martinez J.
    Krishnan, A.
    Delforge, M.
    Trancucci, D.
    Verona, R., I
    Stephenson, T.
    Chastain, K.
    Sidana, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124
  • [33] Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raje, Noopur S.
    Jakubowiak, Andrzej
    Gasparetto, Cristina
    Cornell, Robert F.
    Krupka, Heike I.
    Navarro, Daniel
    Forgie, Alison J.
    Udata, Chandrasekhar
    Basu, Cynthia
    Chou, Jeffrey
    Leung, Abraham
    Lesokhin, Alexander M.
    BLOOD, 2019, 134
  • [34] Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
    Nooka, Ajay K.
    Moreau, Philippe
    Usmani, Saad Zafar
    Garfall, Alfred L.
    Van De Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Oriol Rocafiguera, Albert
    Chari, Ajai
    Karlin, Lionel
    Mateos, Maria-Victoria
    Popat, Rakesh
    Martinez, Joaquin
    Sidana, Surbhi
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Uhlar, Clarissa
    Stephenson, Tara
    Banerjee, Arnob
    Krishnan, Amrita Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Popat, Rakesh
    Usmani, Saad Z.
    Garfall, Alfred
    van de Donk, Niels
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Moreau, Philippe
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36
  • [36] A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    D'Souza, Anita
    Shah, Nina
    Rodriguez, Cesar
    Voorhees, Peter M.
    Bueno, Orlando F.
    Ben Buelow
    Freise, Kevin J.
    Yue, Susan
    Pothacamury, Rajvineeth Kumar
    Polepally, Akshanth R.
    Vij, Ravi
    BLOOD, 2021, 138
  • [37] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Garfall, Alfred L.
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca I.
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
  • [38] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Raab, M. S.
    Haenel, M.
    Mohty, M.
    Tomasson, M. H.
    Arnulf, B.
    Bahlis, N. J.
    Prince, H. M.
    Niesvizky, R.
    Rodriguez-Otero, P.
    Martinez-Lopez, J.
    Koehne, G.
    Jethava, Y.
    Gabayan, A. E.
    Stevens, D. A.
    Nooka, A. K.
    Raje, N.
    Iida, S.
    Leip, E.
    Conte, U.
    Czibere, A.
    Viqueira, A.
    Lesokhin, A. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
  • [39] Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/ Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, Afshin E.
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos
    Viqueira, Andrea
    Lesokhin, Alexander M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S493 - S494
  • [40] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Ahsan, Aarif
    Mantis, Christine
    Luo, Xizhi
    Zhang, Catherine C.
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Kumar, Shaji
    Bueno, Orlando Felix
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Ross, Jeremy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345